Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
April 15, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Melatonin is generally safe for short-term use and unlikely to cause dependence or reduced effectiveness over time — unlike many prescription sleep aids
  • The most common side effects are headache, dizziness, nausea, and daytime drowsiness; less common effects include vivid dreams, mood swings, stomach cramps, and a raised risk of falls
  • Melatonin interacts with a significant list of medications including blood thinners, anticonvulsants, birth control, diabetes drugs, immunosuppressants, and high blood pressure medicine
  • Over-the-counter melatonin supplements vary widely in actual melatonin content — consulting a healthcare provider before use is recommended, especially for anyone on other medications

What Happened?

Melatonin is a naturally occurring hormone that signals the body to prepare for sleep, with blood levels peaking at night. Supplemental melatonin has become one of the most widely used sleep aids globally, available over the counter in most markets. According to Mayo Clinic’s guidance, research supports its usefulness for specific conditions — delayed sleep phase disorder, insomnia, and jet lag — but evidence for broader or long-term use remains limited. Critically, OTC melatonin supplements vary widely in the actual dose delivered, making self-selection unreliable without professional guidance. The most common side effects — headache, dizziness, nausea, and daytime drowsiness — are manageable for most users, but a longer list of less common effects and drug interactions can make it inappropriate for many people without medical review.

Why It Matters?

Melatonin’s reputation as a “natural” and therefore automatically safe supplement is widely overstated. The drug interaction list is substantial: melatonin can interfere with blood thinners, seizure medications, birth control pills, high blood pressure drugs, diabetes medications, immunosuppressants, and any medication processed by the liver — a category that covers a large portion of commonly prescribed drugs. Less recognized side effects including urinary incontinence, raised seizure risk, confusion, and increased fall risk are especially relevant for older adults, who are both the highest users of sleep aids and the most vulnerable to these adverse outcomes. The long-term safety profile also remains inadequately studied, making chronic use a less well-understood risk than most consumers realize.

What’s Next?

Mayo Clinic recommends against using melatonin as a first-line or standalone solution for sleep problems. The evidence-backed approach combines melatonin — when appropriate — with lifestyle interventions: consistent sleep hygiene, regular exercise, good nutrition, stress reduction practices, and social connection. For anyone already on prescription medications, a conversation with a healthcare provider before starting melatonin is not optional advice — it is a genuine clinical necessity given the breadth of documented drug interactions.

Source: Mayo Clinic

Previous Post

A Major European Bank Just Brought Its Stablecoin to Millions of Crypto Wallets — But Can It Compete?

Next Post

China Beat Q1 Growth Targets With 5% GDP — But the Iran War Is Already Eroding the Foundation

Recommended For You

AI-Discovered Drug Reverses Biological Aging by Up to 6 Years in Mid-Stage Trial, Nature Biotechnology Study Finds

by Team Lumida
1 day ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Insilico Medicine's rentosertib — an AI-designed lung disease drug — reduced biological age by up to six years in a 42-patient mid-stage trial, per a Nature Biotechnology study,...

Read more

Oura Faces Class-Action Over Sleep Data Accuracy — And the Whole Wearables Industry Is Watching

by Team Lumida
2 days ago
person clicking Apple Watch smartwatch

A proposed class-action lawsuit alleges Oura's ring failed to reliably track sleep — raising questions about the gap between wearable health trackers' marketing promises and what their data...

Read more

Employer Healthcare Costs Projected to Rise 9.5% in 2027 — Fourth Consecutive Year of Near-Double-Digit Increases

by Team Lumida
1 week ago
doctor holding red stethoscope

Average healthcare costs are projected to reach more than $19,000 per employee in 2027, a 9.5% year-over-year increase, according to Aon. This marks the fourth consecutive year of...

Read more

US Alcohol Consumption Holds at Historic Low as Majority of Americans Now Say Drinking Is Bad for Health

by Team Lumida
3 weeks ago
clear drinking glass with ice cubes

A Gallup poll of 1,200 adults finds 54% of Americans consume alcohol — matching last year's historic low and halting three consecutive annual declines — while 51% now...

Read more

Big Food’s GLP-1 Reckoning: Conagra, Kraft, and Packaged-Food Giants Reformulate for the Not-So-Hungry

by Team Lumida
3 weeks ago
pasta with red sauce on white ceramic round plate

As GLP-1 weight-loss drugs suppress appetite across millions of households, packaged-food companies are retooling recipes, portion sizes, and sensory profiles to win over consumers who eat less but...

Read more

Novo Nordisk Tests Low-Dose Wegovy Pills as Most Patients Already Stick to Smallest Doses

by Team Lumida
3 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has launched a 450-person trial to determine the minimum effective dose of its oral Wegovy pill — a clinically significant shift given that more than two-thirds...

Read more

4 in 5 Americans Say Healthcare Costs Are the Nation’s Top Health Problem — and Nobody Agrees on Who Should Fix It

by Team Lumida
3 weeks ago
doctor holding red stethoscope

A Commonwealth Fund survey of 25,873 adults finds near-universal alarm over health insurance premiums and out-of-pocket costs, even as ACA marketplace premiums surge 58% in 2026 and nearly...

Read more

Wealthy, Healthy, and Ready to Spend: Baby Boomers Are Driving a Global Travel Boom the Industry Is Racing to Serve

by Team Lumida
3 weeks ago
couple kissing on the road during daytime

Baby boomers — flush with retirement savings and in better health than previous generations — are fueling a high-end travel surge, with the industry responding with private-plane tours,...

Read more

385 Million Patient Records Breached and Counting — DentaQuest’s 15M-Person Hack Leads a New Wave of Healthcare Cybersecurity Disasters

by Team Lumida
4 weeks ago
person sitting while using laptop computer and green stethoscope near

The updated Healthcare Dive breach tracker reveals a sector in crisis: DentaQuest's 15M breach in 2026, Conduent's 62M in 2025, and Change Healthcare's record 192.7M in 2024.

Read more

Healthcare Stocks Are Now an Implicit AI Short — Semiconductors and Pharma Have Flipped to Negative Correlation

by Team Lumida
4 weeks ago
turned on monitoring screen

A structural shift is underway in equity markets: the VanEck Semiconductor ETF and the State Street Health Care ETF have moved into negative correlation, meaning healthcare has effectively...

Read more
Next Post
China’s Bold Economic Moves: What You Need to Know Now

China Beat Q1 Growth Targets With 5% GDP — But the Iran War Is Already Eroding the Foundation

OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

The Man Who Attacked OpenAI's HQ Had Talked About 'Luigi-ing Tech CEOs' Months Before

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

text

Could Trump’s Second Term Boost Your Portfolio?

July 9, 2024
China’s Housing Market: Eased Policies Show Promise Amid Economic Struggles

Owning a Home Now Costs 39% More Than in 2019 — and It’s Getting Worse

June 22, 2026
M&A Frenzy Nears $4.5T in 2025 as Regulators Ease—Bankers Warn of an AI-Driven Hangover

M&A Frenzy Nears $4.5T in 2025 as Regulators Ease—Bankers Warn of an AI-Driven Hangover

December 15, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018